Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Kissei Pharmaceutical Co Company

4547.T
JP3240600001
881370

Price

3,700.00
Today +/-
+0.28
Today %
+1.22 %
P

Kissei Pharmaceutical Co stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Kissei Pharmaceutical Co stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Kissei Pharmaceutical Co stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Kissei Pharmaceutical Co stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Kissei Pharmaceutical Co's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Kissei Pharmaceutical Co Stock Price History

DateKissei Pharmaceutical Co Price
10/4/20243,700.00 undefined
10/3/20243,655.00 undefined
10/2/20243,560.00 undefined
10/1/20243,610.00 undefined
9/30/20243,545.00 undefined
9/27/20243,570.00 undefined
9/26/20243,615.00 undefined
9/25/20243,535.00 undefined
9/24/20243,535.00 undefined
9/20/20243,490.00 undefined
9/19/20243,495.00 undefined
9/18/20243,490.00 undefined
9/17/20243,440.00 undefined
9/13/20243,475.00 undefined
9/12/20243,480.00 undefined
9/11/20243,445.00 undefined
9/10/20243,555.00 undefined
9/9/20243,540.00 undefined

Kissei Pharmaceutical Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Kissei Pharmaceutical Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Kissei Pharmaceutical Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Kissei Pharmaceutical Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Kissei Pharmaceutical Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Kissei Pharmaceutical Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Kissei Pharmaceutical Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Kissei Pharmaceutical Co’s growth potential.

Kissei Pharmaceutical Co Revenue, EBIT and net profit per share

DateKissei Pharmaceutical Co RevenueKissei Pharmaceutical Co EBITKissei Pharmaceutical Co Net Income
2027e90.2 B undefined0 undefined8.08 B undefined
2026e86.61 B undefined7.47 T undefined9.83 B undefined
2025e84.98 B undefined6.87 T undefined12.19 B undefined
202475.58 B undefined4.02 B undefined11.16 B undefined
202367.49 B undefined-1.13 B undefined10.53 B undefined
202265.38 B undefined-1.4 B undefined12.92 B undefined
202169.04 B undefined1.51 B undefined5.29 B undefined
202063.23 B undefined1.86 B undefined2.82 B undefined
201972.3 B undefined6.2 B undefined5.48 B undefined
201874.01 B undefined9.89 B undefined9.05 B undefined
201771.71 B undefined8.49 B undefined7.73 B undefined
201671.29 B undefined10.27 B undefined8.17 B undefined
201570.11 B undefined8.33 B undefined7.17 B undefined
201470.4 B undefined12.3 B undefined9.09 B undefined
201362.49 B undefined7.76 B undefined5.02 B undefined
201264.62 B undefined7.47 B undefined4.77 B undefined
201164.39 B undefined6.46 B undefined4 B undefined
201062.18 B undefined6.59 B undefined4.37 B undefined
200964.54 B undefined6.38 B undefined2.06 B undefined
200861.48 B undefined4.27 B undefined2.33 B undefined
200764.22 B undefined2.59 B undefined1.57 B undefined
200664.01 B undefined1.88 B undefined2.03 B undefined
200560.93 B undefined5.52 B undefined4.7 B undefined

Kissei Pharmaceutical Co Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (T)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (M)DOCUMENTS
19941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025e2026e2027e
51.0456.2357.9359.1156.6955.9757.0358.9459.9359.5358.2360.9364.0164.2261.4864.5462.1864.3964.6262.4970.470.1171.2971.7174.0172.363.2369.0465.3867.4975.5884.9886.6190.2
-10.183.012.04-4.10-1.261.883.341.68-0.67-2.194.655.040.32-4.264.97-3.653.560.35-3.2912.65-0.411.690.583.21-2.31-12.549.19-5.313.2311.9812.431.934.14
76.8975.3674.1269.3472.0071.1672.1170.9667.6166.5963.3361.3855.8056.2962.9263.2265.0765.0764.5666.1667.0765.6866.9265.0365.0363.0255.1847.3947.7847.9749.41---
39.2442.3842.9340.9940.8139.8341.1241.8240.5239.6436.8737.435.7236.1538.6840.840.4641.941.7241.3547.2246.0547.7146.6348.1345.5634.8932.7231.2432.3837.34000
0.010.010.010.010.010.010.010.010.010.010.010.010000.010.010.010.010.010.010.010.010.010.010.0100-0-006.877.470
25.8925.7525.0521.7820.3320.6322.0516.6111.6110.2010.679.062.934.046.949.8910.5910.0411.5512.4217.4711.8914.4111.8413.368.582.942.18-2.14-1.675.318,082.388,629.09-
4.746.436.936.075.445.335.724.384.842.25.564.72.031.572.332.064.3744.775.029.097.178.177.739.055.482.825.2912.9210.5311.1612.199.838.08
-35.827.72-12.42-10.41-1.917.31-23.4510.36-54.43152.27-15.47-56.89-22.5148.15-11.39112.08-8.4019.115.2481.17-21.2013.96-5.3817.07-39.40-48.6087.61144.48-18.526.009.19-19.33-17.85
----------------------------------
----------------------------------
42475262666565646364646464615957545452515150.4148.9348.6748.0546.7246.7246.6746.1246.1245.26000
----------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Kissei Pharmaceutical Co Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Kissei Pharmaceutical Co is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (B)OTHER REC. (B)INVENTORIES (B)OTHER CURRENT LIAB. (B)CURRENT ASSETS (B)TANGIBLE ASSETS (B)LONG-T. INVEST. (B)LONG-T. REC. (B)INTANGIBLE ASSETS (B)GOODWILL (M)OTHER NON-CURRENT ASSETS (B)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (B)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (B)OTHER EQUITY (B)UNREAL. GAINS/LOSSES (B)EQUITY (B)LIABILITIES (B)PROVISIONS (B)OTHER SHORT-TERM LIAB. (B)SHORT-TERM DEBTS (B)LONG-TERM DEBT PORTION (B)SHORT-TERM REC. (B)LONG-T. LIAB. (B)DEFERRED TAXES (B)OTHER LIAB. (B)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
1994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024
                                                             
39.4238.9840.5946.3742.3745.2459.1947.3444.2748.4551.4250.4457.4247.6245.9543.1648.7450.6245.8351.2858.3152.3750.1448.1547.6649.3659.6744.4553.1549.645.93
21.4523.4225.224.4222.8122.4723.1627.6727.6224.0124.5926.1525.1927.9423.3423.0122.052326.062523.7123.6724.9724.7328.8726.9619.4623.0622.8122.7828.68
3.52000000000000000000000000000000
4.45.116.075.296.365.376.46.277.28.388.739.812.6610.8810.1210.328.5311.019.9611.1212.8114.6517.3816.7215.9313.9613.4420.1218.9922.826.3
710.3612.9323.1120.9920.869.7210.9111.898.678.97.367.197.286.155.536.325.234.944.866.066.677.577.625.75.494.115.344.45.473.64
75.7977.8784.7999.1892.5393.9498.4792.1990.9889.593.6493.74102.4693.7285.5682.0385.6489.8586.7992.26100.8997.36100.0597.2298.1695.7896.6892.9799.34100.64104.55
25.4629.6529.6631.3330.5929.8729.3729.5828.8428.2228.1727.7928.6530.6329.5928.3727.8327.126.826.5326.9626.8526.7626.3126.425.524.6124.2924.0724.5824.86
5.946.16.57.229.229.519.7219.2325.7322.4732.0134.9235.831.8827.7223.1329.6124.4326.3938.0941.6754.4162.3658.3481.1986.96105.16138.1396.6374.77106.36
0.510000000001.681.630.660.620.590.490.380.160.140.120.140.1300.120.10.120.040.0100.010.01
0.030.030.030.030.030.031.081.082.912.692.663.843.593.863.12.251.811.380.950.820.690.790.811.851.721.521.511.641.571.511.68
000000000000000000000000000000309
3.95.655.924.864.985.5887.17.278.74.683.022.962.884.013.911.763.333.312.212.31.953.252.973.253.643.8111.8216.4719.723.16
35.8441.4342.1143.4444.8244.9948.1756.9964.7662.0769.271.271.6569.866558.1561.3856.457.667.7771.7684.1293.1889.58112.66117.74135.12175.9138.75120.56156.38
111.63119.3126.89142.63137.35138.93146.64149.18155.73151.57162.84164.94174.11163.58150.55140.17147.02146.24144.39160.03172.65181.48193.23186.8210.82213.52231.79268.86238.09221.2260.93
                                                             
23.9223.9223.9924.2224.2224.2224.2224.2224.2224.2224.2224.2224.2224.2224.2724.3624.3624.3624.3624.3624.3624.3624.3624.3624.3624.3624.3624.3624.3624.3624.36
23.8123.8123.8924.1124.1124.1124.1124.1124.1124.1124.1124.1124.1124.1124.1624.2524.2524.2524.2524.2524.2524.2524.2524.2324.2324.2324.2324.2324.2324.2324.23
22.7128.7134.8239.9544.4548.9257.1258.4961.66367.8171.3471.3971.5372.4172.8975.5877.880.7283.8390.9295.5796.23101.76102.83106.03106.46109.27118.18125.58127.31
00000000000000000000-0.981.34-1.73-1.31-0.86-1.06-1.680.022.442.264.56
00000001.210.350.344.398.67.361.991.044.181.682.5410.812.7221.52021.2736.7540.3350.7174.3545.130.3952.78
70.4476.4482.788.2892.7897.25105.45108.02110.27111.63120.14124.06128.32127.22122.83122.55128.37128.08131.86143.24151.27167.03143.1170.29187.31193.87204.07232.23214.3206.81233.24
3.014.024.355.925.85.25.476.067.577.497.218.449.199.554.355.75.625.234.54.885.396.055.834.854.894.355.247.914.14.624.89
1.791.71.831.891.892.011.861.831.812.041.751.991.41.461.881.952.072.152.042.182.652.172.212.112.251.991.871.831.721.681.86
10.8412.5412.447.889.087.917.854.427.424.147.575.587.097.645.765.886.26.26.026.527.978.849.696.858.475.598.046.6311.167.039.42
00000000000000000001.881.761.731.731.731.731.731.731.731.641.491.34
1.01013.0611.551.221.611.531.781.832.112.272.2812.252.4914.422.42.212.322.10.120.110.150.150.110.110.140.150.140.120.150.15
16.6418.2631.6827.251816.7416.7114.118.6315.7718.7918.2929.9321.1426.4115.9316.1115.914.6615.5817.8818.9319.6115.6617.4513.817.0218.2518.7414.9617.66
22.1121.8710.192524.923.2722.5822.5222.3722.0321.9621.9212.312.270.40.841.291.771.551.531.411.611.591.732.12.20.390.30.230.320.24
0000000000002.492.03000.17003.13.827.347.45.659.9411.3917.1928.4816.2610.4321.19
2.442.752.322.111.681.691.794.444.795.045.734.555.034.914.974.995.224.644.795.046.722.886.635.995.253.434.221.880.680.690.71
24.5424.6112.5127.1126.5724.9624.3726.9627.1527.0827.6926.4719.8319.215.375.836.696.416.349.6711.9511.8315.6113.3617.2817.0121.830.6617.1611.4322.13
41.1942.8744.254.3644.5841.741.0841.0645.7942.8546.4844.7649.7640.3531.7821.7622.7922.312125.2429.8330.7635.2229.0234.7330.8238.8248.9135.9126.3939.79
111.63119.31126.9142.63137.36138.94146.53149.08156.06154.48166.62168.82178.08167.57154.61144.31151.17150.39152.86168.48181.1197.8178.32199.31222.04224.69242.9281.13250.21233.2273.03
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Kissei Pharmaceutical Co provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Kissei Pharmaceutical Co's financial health and stability.

Assets

Kissei Pharmaceutical Co's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Kissei Pharmaceutical Co must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Kissei Pharmaceutical Co after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Kissei Pharmaceutical Co's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (B)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (B)NON-CASH ITEM (B)PAID INTEREST (M)PAID TAXES (B)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (B)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
10.578.248.724.59.627.983.593.174.473.366.626.338.077.9913.410.4711.1410.1211.77.124.637.4816.5113.68
3.273.123.113.082.873.013.143.233.863.713.232.812.642.392.192.22.342.372.492.612.563.153.734.11
000000000000000000000000
-9.85-12.4-2.04-1.61-0.9-4.76-1.58-1.36-2.233.20.66-4.77-5.08-1.25-3.2-3.57-6.93-4.29-3.84-2.129.48-7.19-0.58-9.87
2.162.361.951.86-0.55-1.63-1.45-1.080.331.310.190.31-0.580.16-0.44-2.43-0.78-1.76-1.51-1.26-2.74-5.98-18.12-14.6
2532112052032042032131771611054659423937333124232323232320
6.387.152.134.780.754.842.020.951.911.913.611.893.063.395.452.993.412.454.021.050.652.575.7
6.151.3211.747.8411.044.63.693.966.4311.5810.694.695.059.2911.956.675.766.448.856.3513.93-2.541.53-6.68
-1,699-2,426-3,427-1,651-2,427-3,569-3,088-5,279-2,861-1,211-2,290-2,011-1,976-1,883-2,108-2,365-2,281-2,532-2,120-1,333-1,302-1,485-1,919-2,547
6.234.5-13.18-1.07-6.06-4.55-1.571.6-3.06-1.66-3.04-1.94-2.78-2.08-2.32-3.17-5.69-4.67-2.96-2.090.49-9.3310.786
7.936.92-9.760.58-3.63-0.981.526.88-0.2-0.45-0.750.07-0.8-0.19-0.21-0.8-3.4-2.14-0.84-0.751.79-7.8412.78.55
000000000000000000000000
-758190-104-5585-35-216-9,779160-11,520115523-458-131-293-64-3985114-16-2,035-220-218-283
-4-2,150-1,315-2,559-877-103-79-55-88-89-36-3-4,340-1-3-7,906-2-1,649-4,46400-1,30300
-1,498-2,768-2,217-3,400-1,557-1,225-1,490-11,245-1,447-13,183-1,604-1,271-6,649-2,038-2,304-10,081-2,146-3,766-6,621-2,306-4,419-4,000-2,756-3,420
13800000-100000-2-2-1-1-2-1-1-1-2-2-2-2
-874-808-798-786-765-1,087-1,194-1,411-1,519-1,574-1,683-1,791-1,849-1,904-2,007-2,110-2,103-2,201-2,270-2,289-2,382-2,475-2,536-3,135
10.883.04-3.663.373.39-1.190.66-5.691.92-3.266.051.47-4.385.187.31-6.12-2.05-2-0.741.9510-15.879.56-4.12
4,453-1,1098,3126,1878,6151,027603-1,3203,56910,3678,4002,6773,0707,4039,8374,3023,4833,9096,7255,01312,631-4,028-386-9,227
000000000000000000000000

Kissei Pharmaceutical Co stock margins

The Kissei Pharmaceutical Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Kissei Pharmaceutical Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Kissei Pharmaceutical Co.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Kissei Pharmaceutical Co's sales revenue. A higher gross margin percentage indicates that the Kissei Pharmaceutical Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Kissei Pharmaceutical Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Kissei Pharmaceutical Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Kissei Pharmaceutical Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Kissei Pharmaceutical Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Kissei Pharmaceutical Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Kissei Pharmaceutical Co Margin History

Kissei Pharmaceutical Co Gross marginKissei Pharmaceutical Co Profit marginKissei Pharmaceutical Co EBIT marginKissei Pharmaceutical Co Profit margin
2027e49.41 %0 %8.95 %
2026e49.41 %8,629.09 %11.35 %
2025e49.41 %8,082.38 %14.34 %
202449.41 %5.31 %14.77 %
202347.97 %-1.67 %15.6 %
202247.78 %-2.14 %19.76 %
202147.39 %2.18 %7.65 %
202055.18 %2.94 %4.45 %
201963.02 %8.58 %7.58 %
201865.03 %13.36 %12.22 %
201765.03 %11.84 %10.77 %
201666.92 %14.41 %11.45 %
201565.68 %11.89 %10.22 %
201467.07 %17.47 %12.92 %
201366.16 %12.42 %8.03 %
201264.56 %11.55 %7.38 %
201165.07 %10.04 %6.22 %
201065.07 %10.59 %7.03 %
200963.22 %9.89 %3.19 %
200862.92 %6.94 %3.78 %
200756.29 %4.04 %2.44 %
200655.8 %2.93 %3.17 %
200561.38 %9.06 %7.71 %

Kissei Pharmaceutical Co Stock Sales Revenue, EBIT, Earnings per Share

The Kissei Pharmaceutical Co earnings per share therefore indicates how much revenue Kissei Pharmaceutical Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Kissei Pharmaceutical Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Kissei Pharmaceutical Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Kissei Pharmaceutical Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Kissei Pharmaceutical Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Kissei Pharmaceutical Co Revenue, EBIT and net profit per share

DateKissei Pharmaceutical Co Sales per ShareKissei Pharmaceutical Co EBIT per shareKissei Pharmaceutical Co Earnings per Share
2027e2,040.41 undefined0 undefined182.71 undefined
2026e1,959.36 undefined0 undefined222.4 undefined
2025e1,922.28 undefined0 undefined275.68 undefined
20241,669.95 undefined88.76 undefined246.58 undefined
20231,463.58 undefined-24.48 undefined228.3 undefined
20221,417.78 undefined-30.4 undefined280.19 undefined
20211,479.54 undefined32.25 undefined113.25 undefined
20201,353.58 undefined39.75 undefined60.3 undefined
20191,547.59 undefined132.76 undefined117.33 undefined
20181,540.25 undefined205.76 undefined188.24 undefined
20171,473.22 undefined174.45 undefined158.73 undefined
20161,457.15 undefined209.99 undefined166.88 undefined
20151,390.77 undefined165.32 undefined142.13 undefined
20141,380.37 undefined241.2 undefined178.29 undefined
20131,225.31 undefined152.18 undefined98.41 undefined
20121,242.65 undefined143.56 undefined91.71 undefined
20111,192.46 undefined119.69 undefined74.15 undefined
20101,151.44 undefined121.94 undefined80.94 undefined
20091,132.19 undefined111.96 undefined36.16 undefined
20081,042.03 undefined72.36 undefined39.42 undefined
20071,052.71 undefined42.52 undefined25.74 undefined
20061,000.11 undefined29.33 undefined31.66 undefined
2005952.08 undefined86.23 undefined73.44 undefined

Kissei Pharmaceutical Co business model

Kissei Pharmaceutical Co., Ltd. is a leading innovative company in Japan that focuses on the development and production of pharmaceuticals for various diseases. The Kissei Group consists of several companies that work together in the development and production of pharmaceuticals and other medical products. History: Kissei Pharmaceutical was founded in 1946 in Matsumoto, Japan. The company initially manufactured drugs for skin and respiratory diseases and later expanded its portfolio to include drugs for cancer and Parkinson's. Over time, Kissei Pharmaceutical has also invested in research and development and has become a key player in the global pharmaceutical industry. Business model: Kissei Pharmaceutical's business model is based on the development and marketing of innovative drugs for various diseases. The company's strategy is to focus on niche markets and invest in research and development to develop groundbreaking drugs. The company also seeks partnerships and has a strong presence in the Asian market. Divisions: Kissei Pharmaceutical is divided into various business areas, including cancer, neurological disorders, metabolic disorders, and dermatological diseases. The largest business area is oncology, where the company offers many products for the treatment of cancer. The neurology division includes products for the treatment of Parkinson's and Alzheimer's. In the field of metabolic disorders, Kissei Pharmaceutical offers drugs for the treatment of diabetes and obesity. In dermatology, the products include skincare products for various skin conditions such as eczema and psoriasis. Products: Kissei Pharmaceutical offers a wide range of pharmaceutical products for a variety of diseases. In the field of oncology, the company produces drugs such as docetaxel for breast and lung cancer, and irinotecan for colon cancer. In the field of neurological disorders, Kissei Pharmaceutical produces drugs such as levodopa for Parkinson's, and TAK-659 for cancer patients with high blood sugar levels. In the field of metabolic disorders, the company produces drugs such as insulin for the treatment of diabetes, and leptin for the treatment of obesity. In dermatology, Kissei Pharmaceutical produces drugs such as epicederm for eczema and psoriasis, and apimo for acne. Conclusion: Kissei Pharmaceutical is an innovative company in Japan that specializes in the development and production of pharmaceuticals for various diseases. The company has a strong presence in the Asian market and works closely with partners to develop new drugs. With its various business divisions and wide range of products, Kissei Pharmaceutical is a key player in the global pharmaceutical industry. Kissei Pharmaceutical Co is one of the most popular companies on Eulerpool.com.

Kissei Pharmaceutical Co SWOT Analysis

Strengths

Kissei Pharmaceutical Co Ltd holds a strong market position in the pharmaceutical industry, backed by decades of experience and a well-established reputation.

The company enjoys a diversified product portfolio, offering a range of innovative and high-quality pharmaceuticals in various therapeutic areas.

Kissei Pharmaceutical has a robust research and development (R&D) department, consistently investing in cutting-edge technology and scientific advancements.

The company's strong distribution network enables efficient product delivery to a wide customer base, both domestically and internationally.

Weaknesses

Kissei Pharmaceutical faces intense competition from both domestic and international pharmaceutical companies, which may hinder its market share growth.

The company heavily relies on a few key products for a significant portion of its revenue, making it vulnerable to potential product-related risks or market fluctuations.

Kissei Pharmaceutical's international presence is relatively limited compared to some global competitors, potentially impacting its ability to capitalize on emerging markets.

Opportunities

The growing global demand for pharmaceutical products presents an opportunity for Kissei Pharmaceutical to expand its market presence and increase revenue.

Investing in research and development of new drug candidates could lead to the introduction of breakthrough therapies, driving market differentiation and growth.

Collaborations and partnerships with other pharmaceutical companies or research institutions can enhance Kissei Pharmaceutical's access to new technologies and expertise.

Threats

Government regulations and policies related to the pharmaceutical industry, including pricing controls and intellectual property rights, can pose challenges for Kissei Pharmaceutical.

The ongoing COVID-19 pandemic and its potential long-term impacts on healthcare systems and drug development can affect the company's operations and financial performance.

Fluctuating currency exchange rates and economic uncertainties in key markets may adversely affect Kissei Pharmaceutical's international business and profitability.

Kissei Pharmaceutical Co Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Kissei Pharmaceutical Co historical P/E ratio, EBIT multiple, and P/S ratio

Kissei Pharmaceutical Co shares outstanding

The number of shares was Kissei Pharmaceutical Co in 2023 — This indicates how many shares 46.115 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Kissei Pharmaceutical Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Kissei Pharmaceutical Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Kissei Pharmaceutical Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Kissei Pharmaceutical Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Kissei Pharmaceutical Co stock splits

In Kissei Pharmaceutical Co's history, there have been no stock splits.

Kissei Pharmaceutical Co dividend history and estimates

In 2023, Kissei Pharmaceutical Co paid a dividend amounting to 81 JPY. Dividend means that Kissei Pharmaceutical Co distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Kissei Pharmaceutical Co provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Kissei Pharmaceutical Co’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Kissei Pharmaceutical Co's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Kissei Pharmaceutical Co Dividend History

DateKissei Pharmaceutical Co Dividend
2027e89.18 undefined
2026e89.02 undefined
2025e89.31 undefined
202486 undefined
202381 undefined
202268 undefined
202155 undefined
202053 undefined
201951 undefined
201849 undefined
201747 undefined
201645 undefined
201543 undefined
201441 undefined
201339 undefined
201237 undefined
201135 undefined
201033 undefined
200930 undefined
200828 undefined
200726 undefined
200624 undefined
200522 undefined

Kissei Pharmaceutical Co dividend payout ratio

In 2023, Kissei Pharmaceutical Co had a payout ratio of 53.58%. The payout ratio indicates the percentage of the company's profits that Kissei Pharmaceutical Co distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Kissei Pharmaceutical Co represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Kissei Pharmaceutical Co could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Kissei Pharmaceutical Co's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Kissei Pharmaceutical Co Payout Ratio History

DateKissei Pharmaceutical Co Payout ratio
2027e42.46 %
2026e45.24 %
2025e39.99 %
202442.14 %
202353.58 %
202224.27 %
202148.56 %
202087.89 %
201943.47 %
201826.03 %
201729.61 %
201626.97 %
201530.25 %
201423 %
201339.63 %
201240.34 %
201147.21 %
201040.77 %
200982.99 %
200871.03 %
2007101.05 %
200675.83 %
200529.96 %
Unfortunately, there are currently no price targets and forecasts available for Kissei Pharmaceutical Co.

Kissei Pharmaceutical Co latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/202459.39 92.89  (56.41 %)2025 Q1
3/31/2024111.87 63.78  (-42.99 %)2024 Q4
12/31/202354.2 59.18  (9.19 %)2024 Q3
9/30/202351.92 52.66  (1.41 %)2024 Q2
6/30/202356.76 70.95  (25 %)2024 Q1
12/31/202219.19 72.45  (277.54 %)2023 Q3
9/30/202224.24 36.67  (51.27 %)2023 Q2
6/30/202244.69 35.47  (-20.64 %)2023 Q1
12/31/20214.04 25  (518.91 %)2022 Q3
9/30/202132.32 43.85  (35.66 %)2022 Q2
1
2
3

Kissei Pharmaceutical Co shareholders

%
Name
Stocks
Change
Date
5.06727 % The Dai-ichi Life Insurance Company, Limited2,240,00009/30/2023
4.98452 % Hachijuni Bank Ltd2,203,420-97,0003/15/2024
3.79593 % Kanzawa Co.1,678,00009/30/2023
3.48827 % Kanzawa (Mutsuo)1,542,00009/30/2023
2.91368 % Kissei Pharmaceutical Company Ltd. Group Employees1,288,000-39,0009/30/2023
2.76438 % Naberin & Co.1,222,00009/30/2023
2.34465 % The Vanguard Group, Inc.1,036,459140,4003/31/2024
2.31999 % Nomura Asset Management Co., Ltd.1,025,55656,7003/31/2024
2.24792 % JPMorgan Asset Management U.K. Limited993,70002/29/2024
2.06763 % Shionogi & Co Ltd914,00009/30/2023
1
2
3
4
5
...
10

Most common questions regarding Kissei Pharmaceutical Co

What values and corporate philosophy does Kissei Pharmaceutical Co represent?

Kissei Pharmaceutical Co Ltd represents a commitment to improving global health through its values and corporate philosophy. The company focuses on research and development of innovative pharmaceutical products that contribute to the well-being of individuals and society. Kissei Pharmaceutical Co Ltd strives for excellence, integrity, and accountability in all aspects of its operations. With a strong emphasis on patient-centric healthcare solutions, Kissei Pharmaceutical Co Ltd aims to enhance the quality of life for patients worldwide. By promoting continuous innovation and sustainable practices, the company aims to be a trusted and respected leader in the global pharmaceutical industry.

In which countries and regions is Kissei Pharmaceutical Co primarily present?

Kissei Pharmaceutical Co Ltd is primarily present in Japan.

What significant milestones has the company Kissei Pharmaceutical Co achieved?

Kissei Pharmaceutical Co Ltd has achieved various significant milestones throughout its history. Some notable achievements include the development of Lopid, a drug used for lipid metabolism disorders, which gained worldwide recognition. Additionally, the company successfully launched Cravit, an anti-infective agent that became widely prescribed. Kissei Pharmaceutical Co Ltd's commitment to research and development has led to advancements in pharmaceutical technology, resulting in the release of innovative products. The company continues to expand its global presence through collaborations and strategic partnerships. Kissei Pharmaceutical Co Ltd's constant strive for excellence and dedication to improving healthcare has solidified its position as a leading pharmaceutical company.

What is the history and background of the company Kissei Pharmaceutical Co?

Kissei Pharmaceutical Co Ltd is a renowned company with a rich history and background. Founded in 1946, it has evolved and thrived over the years to become a leading pharmaceutical organization based in Japan. Kissei Pharmaceutical focuses on the research, development, and distribution of innovative pharmaceutical products. With a strong commitment to improving healthcare, the company has expanded its global presence, establishing subsidiaries and partnerships worldwide. Kissei Pharmaceutical's dedication to scientific excellence and customer satisfaction has earned them a stellar reputation in the pharmaceutical industry. Their continuous efforts to enhance medical treatments and contribute to society have solidified their position as a trusted and respected healthcare company.

Who are the main competitors of Kissei Pharmaceutical Co in the market?

Kissei Pharmaceutical Co Ltd faces competition from various companies in the market. Some of its main competitors include Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company, Limited, Shionogi & Co., Ltd., and Eisai Co., Ltd. These companies operate in the pharmaceutical industry and offer similar products and services, posing a competitive challenge to Kissei Pharmaceutical Co Ltd. It is important for Kissei Pharmaceutical Co Ltd to continually innovate and deliver high-quality products to stay competitive in the market and retain its position among these industry rivals.

In which industries is Kissei Pharmaceutical Co primarily active?

Kissei Pharmaceutical Co Ltd is primarily active in the pharmaceutical industry.

What is the business model of Kissei Pharmaceutical Co?

The business model of Kissei Pharmaceutical Co Ltd revolves around the development, manufacturing, and marketing of pharmaceutical products. Kissei Pharmaceutical Co Ltd specializes in the research of innovative drugs and strives to improve the health and well-being of individuals through its high-quality and reliable medications. By focusing on various therapeutic areas such as urology, kidney diseases, diabetes, and oncology, Kissei Pharmaceutical Co Ltd aims to address critical medical needs and provide effective treatment options. The company's commitment to research and development, coupled with its strong marketing strategies, enables it to deliver innovative and reliable pharmaceutical solutions to a global consumer base.

What is the P/E ratio of Kissei Pharmaceutical Co 2024?

The Kissei Pharmaceutical Co P/E ratio is 15.01.

What is the P/S ratio of Kissei Pharmaceutical Co 2024?

The Kissei Pharmaceutical Co P/S ratio is 2.22.

What is the Quality Investing of Kissei Pharmaceutical Co?

The Quality Investing for Kissei Pharmaceutical Co is 4/10.

What is the revenue of Kissei Pharmaceutical Co 2024?

The Kissei Pharmaceutical Co revenue is 75.58 B JPY.

How high is the profit of Kissei Pharmaceutical Co 2024?

The Kissei Pharmaceutical Co profit is 11.16 B JPY.

What is the business model of Kissei Pharmaceutical Co

Kissei Pharmaceutical Co Ltd is a Japanese company that has been active in the pharmaceutical business since 1946. The company is headquartered in Matsumoto and has branches in Japan, the USA, and China. Kissei focuses on the development, manufacturing, and marketing of prescription drugs, OTC products, and diagnostics. The three main business divisions of Kissei are the pharmaceutical division, the diagnostics division, and the health and care products division. Within the pharmaceutical division, the company develops and produces a wide range of prescription drugs for the treatment of conditions such as diabetes, pain, allergies, and asthma. Some of the key products of Kissei include: • Avigan: An antiviral medication used for the treatment of influenza and other viral infections. It was also used for the treatment of COVID-19 in 2020. • Fentiazac: An analgesic and anti-inflammatory medication used for the relief of pain in arthritis, inflammation, and injuries. • Glufast: An orally administered medication used for the treatment of type 2 diabetes mellitus. • Sarpul: An antihistamine used for the treatment of allergy symptoms. In the diagnostics division, Kissei offers a wide range of medical diagnostics products, such as immunassays, enzyme immunoassays, DNA tests, and antibody tests. These products are used in medical research and diagnostics. In the health and care products division, Kissei develops and produces a variety of products that promote well-being and health. These include dietary supplements, food, and beverages tailored to the needs of specific population groups (such as the elderly or athletes). Kissei also offers cosmetics tailored to the needs of the skin. Kissei's business model is based on creating value for its customers, shareholders, and employees. The company focuses on research and development to develop innovative products that meet the needs of patients and customers. Kissei works closely with university research institutions and other companies. The company places great importance on compliance with ethical and compliance principles, as well as ensuring the quality and safety of its products. Kissei strives to minimize its environmental impact and promote sustainable business practices. Additionally, the company is committed to responsible corporate governance. Overall, Kissei Pharmaceutical Co Ltd is a globally operating company with a wide portfolio of products and services in the pharmaceutical, diagnostics, and health and care products sectors. The company is dedicated to developing innovative solutions that contribute to the improvement of health and well-being.

What is the Kissei Pharmaceutical Co dividend?

Kissei Pharmaceutical Co pays a dividend of 68 JPY distributed over payouts per year.

How often does Kissei Pharmaceutical Co pay dividends?

The dividend cannot currently be calculated for Kissei Pharmaceutical Co or the company does not pay out a dividend.

What is the Kissei Pharmaceutical Co ISIN?

The ISIN of Kissei Pharmaceutical Co is JP3240600001.

What is the Kissei Pharmaceutical Co WKN?

The WKN of Kissei Pharmaceutical Co is 881370.

What is the Kissei Pharmaceutical Co ticker?

The ticker of Kissei Pharmaceutical Co is 4547.T.

How much dividend does Kissei Pharmaceutical Co pay?

Over the past 12 months, Kissei Pharmaceutical Co paid a dividend of 86 JPY . This corresponds to a dividend yield of about 2.32 %. For the coming 12 months, Kissei Pharmaceutical Co is expected to pay a dividend of 89.31 JPY.

What is the dividend yield of Kissei Pharmaceutical Co?

The current dividend yield of Kissei Pharmaceutical Co is 2.32 %.

When does Kissei Pharmaceutical Co pay dividends?

Kissei Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of October, April, October, April.

How secure is the dividend of Kissei Pharmaceutical Co?

Kissei Pharmaceutical Co paid dividends every year for the past 23 years.

What is the dividend of Kissei Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 89.31 JPY are expected. This corresponds to a dividend yield of 2.41 %.

In which sector is Kissei Pharmaceutical Co located?

Kissei Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Kissei Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Kissei Pharmaceutical Co from 12/1/2024 amounting to 45 JPY, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.

When did Kissei Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 12/1/2024.

What was the dividend of Kissei Pharmaceutical Co in the year 2023?

In the year 2023, Kissei Pharmaceutical Co distributed 81 JPY as dividends.

In which currency does Kissei Pharmaceutical Co pay out the dividend?

The dividends of Kissei Pharmaceutical Co are distributed in JPY.

All fundamentals about Kissei Pharmaceutical Co

Our stock analysis for Kissei Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Kissei Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.